High materiality7/10
Canaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Jazz Pharmaceuticals target $300; price $260.23; Canaccord Genuity reiterates Buy.
- Target $300; price $260.23; Buy reiterated.
Key facts
- 01
Target: $300
- 02
Posted price: $260.23
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Gary Newman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.